Patients may not have received any other investigational agents within 4 weeks of study entryXx_NEWLINE_xXHave received any investigational new drug within the past 30 days or planning to receive such during the study periodXx_NEWLINE_xXPatients may not be planning to receive any other investigational agentsXx_NEWLINE_xXParticipants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chairXx_NEWLINE_xXPatients who are receiving any other investigational agents or who have received pomalidomide in the pastXx_NEWLINE_xXParticipants who received any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents (replacement doses of steroids for adrenal insufficiency are permitted or treatment with prednisone =< 5 mg/day); receipt of investigational agents within the 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational or approved agents for hepatitis C, are also exclusionaryXx_NEWLINE_xXConcurrent administration of any other investigational agentsXx_NEWLINE_xXPatients must not receive any other investigational agents while on study or within four weeks prior to registrationXx_NEWLINE_xXParticipants who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptableXx_NEWLINE_xXPatients must not be planning to receive any other investigational agents during the course of protocol treatmentXx_NEWLINE_xXPatients must not receive any other investigational agents while on study or within four weeks prior to randomizationXx_NEWLINE_xXUse of any investigational product within 4 weeks prior to randomizationXx_NEWLINE_xXPatients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeksXx_NEWLINE_xXAny other investigational agents within the past 4 weeksXx_NEWLINE_xXPatients should not have received any other investigational agents within the past 4 weeksXx_NEWLINE_xXPatients who are receiving any other investigational agents; all investigational agents other than ibrutinib must have been discontinued at least 4 weeks prior to beginning treatment; prior ibrutinib therapy must have been discontinued at least 2 weeks prior to beginning therapyXx_NEWLINE_xXPatients must not be receiving or planning to receive any other investigational agentsXx_NEWLINE_xXConcurrent anticancer therapy (including other investigational agents)Xx_NEWLINE_xXConcomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapiesXx_NEWLINE_xXPatients must not have received radiation therapy, non-cytotoxic agents or investigational agents or systemic corticosteroids within 14 days prior to registrationXx_NEWLINE_xXParticipants should not have received any other investigational agents nor have participated in an investigational trial within the past 4 weeksXx_NEWLINE_xX